CAHAN - Early Respiratory Syncytial Virus Activity and Use of Palivizumab

The Health Advisory below discusses an early increase in respiratory syncytial virus (RSV) activity in California. Providers are advised to consider testing for additional respiratory pathogens besides SARS-CoV-2, including RSV, and to administer prophylactic palivizumab to high-risk infants and young children per American Academy of Pediatrics guidance.

Link:

https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/.